|
SGOL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.59010000406235E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.9599000001278E-07 |
| Normal-vs-Stage2 |
3.85090004328958E-09 |
| Normal-vs-Stage3 |
1.30700000045003E-07 |
| Normal-vs-Stage4 |
4.88029999967665E-07 |
| Stage1-vs-Stage2 |
2.693600E-02 |
| Stage1-vs-Stage3 |
3.461000E-01 |
| Stage1-vs-Stage4 |
3.970200E-01 |
| Stage2-vs-Stage3 |
1.676600E-01 |
| Stage2-vs-Stage4 |
2.505200E-01 |
| Stage3-vs-Stage4 |
9.076800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.12270000021775E-07 |
| Normal-vs-AfricanAmerican |
7.50270000016151E-07 |
| Normal-vs-Asian |
5.77459999999697E-05 |
| Caucasian-vs-AfricanAmerican |
5.203200E-01 |
| Caucasian-vs-Asian |
3.412400E-01 |
| AfricanAmerican-vs-Asian |
1.861200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.22089999998742E-07 |
| Normal-vs-Female |
1.00239999967222E-07 |
| Male-vs-Female |
7.712400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.13959999995073E-06 |
| Normal-vs-Age(41-60Yrs) |
6.52419995805786E-09 |
| Normal-vs-Age(61-80Yrs) |
1.63740000003187E-07 |
| Normal-vs-Age(81-100Yrs) |
1.301630E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.336000E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.019200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.223800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.485600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.406400E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.901610E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.183200E-01 |
| Classical-VS-Follicular |
1.1872999999829E-06 |
| Classical-VS-Other |
4.112800E-01 |
| Classical-VS-Normal |
1.87480000002349E-06 |
| Tall-VS-Follicular |
2.594000E-02 |
| Tall-VS-Other |
5.636400E-01 |
| Tall-VS-Normal |
6.440200E-04 |
| Follicular-VS-Other |
4.435200E-01 |
| Follicular-VS-Normal |
1.601100363402E-10 |
| Other-VS-Normal |
1.594480E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.93460000241785E-08 |
| Normal-vs-N1 |
9.81049996795491E-09 |
| N0-vs-N1 |
3.852800E-01 |
|
|
